Decoy Therapeutics (DCOY)
NASDAQ:DCOY
Total Valuation
Decoy Therapeutics has a market cap or net worth of $2.99M. The enterprise value is -$7.71M.
Market Cap$2.99M
Enterprise Value-$7.71M
Share Statistics
Decoy Therapeutics has 531,968 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding531,968
Owned by Insiders4.73%
Owned by Institutions―
Financial Efficiency
Decoy Therapeutics’s return on equity (ROE) is -2.13 and return on invested capital (ROIC) is -214.20%.
Return on Equity (ROE)-2.13
Return on Assets (ROA)-1.13
Return on Invested Capital (ROIC)-214.20%
Return on Capital Employed (ROCE)-2.14
Revenue Per Employee0.00
Profits Per Employee-6.26M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Decoy Therapeutics is ―. Decoy Therapeutics’s PEG ratio is 0.00428.
PE Ratio―
PS Ratio0.00
PB Ratio0.64
Price to Fair Value0.64
Price to FCF-0.78
Price to Operating Cash Flow-0.58
PEG Ratio0.00428
Income Statement
In the last 12 months, Decoy Therapeutics had revenue of 0.00 and earned -12.52M in profits. Earnings per share was -25.99.
Revenue0.00
Gross Profit-8.52M
Operating Income-12.61M
Pretax Income-12.52M
Net Income-12.52M
EBITDA-12.61M
Earnings Per Share (EPS)-25.99
Cash Flow
In the last 12 months, operating cash flow was -4.83M and capital expenditures 8.00, giving a free cash flow of -4.83M billion.
Operating Cash Flow-4.83M
Free Cash Flow-4.83M
Free Cash Flow per Share-9.07
Dividends & Yields
Decoy Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.54
52-Week Price Change-94.77%
50-Day Moving Average7.99
200-Day Moving Average46.13
Relative Strength Index (RSI)30.98
Average Volume (3m)356.88K
Important Dates
Decoy Therapeutics upcoming earnings date is Mar 30, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2025
Next Earnings DateMar 30, 2026
Ex-Dividend Date―
Financial Position
Decoy Therapeutics as a current ratio of 2.13, with Debt / Equity ratio of 0.00%
Current Ratio2.13
Quick Ratio2.13
Debt to Market Cap0.00
Net Debt to EBITDA0.85
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Decoy Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Decoy Therapeutics EV to EBITDA ratio is 0.55, with an EV/FCF ratio of 1.44.
EV to Sales0.00
EV to EBITDA0.55
EV to Free Cash Flow1.44
EV to Operating Cash Flow1.44
Balance Sheet
Decoy Therapeutics has $10.71M in cash and marketable securities with $0.00 in debt, giving a net cash position of $10.71M billion.
Cash & Marketable Securities$10.71M
Total Debt$0.00
Net Cash$10.71M
Net Cash Per Share$20.13
Tangible Book Value Per Share$12.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Decoy Therapeutics is $2.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.50
Price Target Upside-55.60% Downside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast68.08%